Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

NCT01525082 is registered in ClinicalTrials.gov with Shaheen Shagufta as lead sponsor.

NCT NCT01525082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01525082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Lead sponsor
Shaheen Shagufta
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
December 31, 2019
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrinoma, glucagonoma, insulinoma, pancreatic polypeptide tumor, recurrent islet cell carcinoma, recurrent pancreatic cancer, somatostatinoma, stage iii pancreatic cancer, stage iv pancreatic cancer